tirzepatide rebound weight gain People Who Stopped Taking the Loss Drug Regained Nearly Half the Weight They Lost Maintain Weight After Tirzepatide: Long-Term

The thermic effect of food decreases

(Special Offer

According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management

Incidence of acute coronary syndromes, cerebral infarction, acute peripheral arterial thrombosis, deep venous thrombosis, and overall arterial cardiovascular events at 5 years served as the primary outcome measures

For patients who dont respond well to GLP1 medications or dont achieve the weight loss theyre hoping for, other treatment paths exist